• Source: Centanafadine

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions.




See also


Amitifadine
Bicifadine
Dasotraline
DOV-216,303
Tesofensine




References






External links


Centanafadine - AdisInsight

Kata Kunci Pencarian:

• Centanafadine
• Methamphetamine
• MDMA
• Ketamine
• Caffeine
• Otsuka Pharmaceutical
• Cocaine
• Methylphenidate
• Modafinil
• Chlorphenamine